Could PD-L1 prove to be an effective therapeutic target for bladder cancer?

Clinical trials For clinicians Genitourinary Journal articles Opinion
clinical trial data charts with statistical analysis, organized and detailed, selective focus, datadriven theme, ethereal, manipulation, modern office backdrop

Highlighting this years’ American Society for Clinical Oncology (ASCO) conference were presentations focusing on T-cell immune checkpoint blockade as a therapeutic target in solid tumors. Promising results in melanoma, lung and renal cancers have led to further disease-specific Phase I and II trials of immune checkpoint blockade in other solid tumors refractory to treatment.

Metastatic urothelial bladder cancer (UBC) is one such tumor; this disease is associated with limited treatment options and a poor prognosis. The last significant advance in metastatic bladder cancer treatment came with the application of cisplatin-based chemotherapies over two decades ago. Despite the widespread use of cisplatin-based combination regimens and improved supportive care, 5 year survival rates for metastatic UBC remain around 15%.

Click here to view full article.